278 related articles for article (PubMed ID: 28849946)
1. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
Pohjantähti-Maaroos H; Hyppölä H; Lekkala M; Sinisalo E; Heikkola A; Hartikainen J
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):114-120. PubMed ID: 28849946
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
Savelieva I; Graydon R; Camm AJ
Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
[TBL] [Abstract][Full Text] [Related]
4. Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation.
Conde D; Costabel JP; Aragon M; Lambardi F; Trivi M
Cardiol J; 2014; 21(3):304-8. PubMed ID: 23990184
[TBL] [Abstract][Full Text] [Related]
5. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
Conde D
Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
Ma W; Guo X; Wang Q; Sun G; Wang J
J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
[TBL] [Abstract][Full Text] [Related]
7. Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion.
Müssigbrodt A; John S; Kosiuk J; Richter S; Hindricks G; Bollmann A
Europace; 2016 Jan; 18(1):51-6. PubMed ID: 26056189
[TBL] [Abstract][Full Text] [Related]
8. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
Stoneman P; Gilligan P; Mahon P; Sheahan R
Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
Akel T; Lafferty J
Ann Noninvasive Electrocardiol; 2018 May; 23(3):e12508. PubMed ID: 29105209
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
11. [Vernakalant for the conversion of atrial fibrillation of recent onset].
Seoane L; Baranchuk A; Conde D
Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
[TBL] [Abstract][Full Text] [Related]
12. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
[TBL] [Abstract][Full Text] [Related]
13. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
[TBL] [Abstract][Full Text] [Related]
14. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
[TBL] [Abstract][Full Text] [Related]
15. Conversion of Atrial Fibrillation after Cardiosurgical Procedures by Vernakalant® as an Atrial Repolarization Delaying Agent (ARDA).
Dalyanoglu H; Mehdiani A; Minol JP; Sipahi NF; Aubin H; Boeken U; Müller A; Makimoto H; Lichtenberg A; Korbmacher B
Heart Surg Forum; 2018 May; 21(3):E201-E208. PubMed ID: 29893681
[TBL] [Abstract][Full Text] [Related]
16. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation.
Conde D; Costabel JP; Caro M; Ferro A; Lambardi F; Corrales Barboza A; Lavalle Cobo A; Trivi M
Int J Cardiol; 2013 Oct; 168(3):2423-5. PubMed ID: 23518212
[TBL] [Abstract][Full Text] [Related]
17. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
[TBL] [Abstract][Full Text] [Related]
18. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
[TBL] [Abstract][Full Text] [Related]
19. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
20. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
